With the accelerated approval of EXONDYS 51™ (aka eteplirsen) by the FDA in September, the Duchenne community has been quickly introduced to a whole new vocabulary and a whole new list of concerns. We knew that achieving an accelerated approval was going to be difficult. But the process of watching policy determinations and caveats to access be administered from health insurers unfamiliar with…